18 December 2020
The NASDAQ Biotechnology Index was launched in 1993 and is designed to track the performance of a set of securities listed on the
About
Syndax's Cautionary Note on Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements relating to Syndax's expectations regarding the completion, timing and size of the proposed public offering. Words such as "may," "will," "expect," "plan," "anticipate," "intend" and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) are intended to identify forward-looking statements. These forward-looking statements are based on Syndax's expectations and assumptions as of the date of this press release. Each of these forward-looking statements involves risks and uncertainties. Actual results may differ materially from these forward-looking statements. These risks and uncertainties include, without limitation, risks and uncertainties related to market conditions and satisfaction of customary closing conditions related to the proposed public offering. There can be no assurance that Syndax will be able to complete the proposed public offering on the anticipated terms, or at all. Other factors that may cause Syndax's actual results to differ from those expressed or implied in the forward-looking statements in this press release are discussed in Syndax's filings with the
New polymer coating for improved cancer targeting of nanomedicine
20 May 2022
Preparation is key: the role of scientific due diligence in successful partnerships
20 May 2022
mRNA Unlocked: How Technology Convergence Is Driving the Next Wave
19 May 2022
Researchers develop battery-free, smart contact lens that delivers glaucoma drugs on demand
18 May 2022